Incyte Corp $ 87.76 -2.87 (-3.17%)
Incyte Corp News and Headlines -
The price of MacroGenics Inc. (MGNX) shares has recently seen a huge jump. After providing an early glimpse of some of the earnings results on May 6, MacroGenics’s stock soared by more than 230% to a two-year high, bringing its market value to nearly $1 billion.
More information on the drugs being studied will be released this week in the form of abstracts. However, in my opinion, we will need to wait for the American Society of Clinical Oncology (aka ASCO) meeting on May 29 to 31 to see whether the increase is justified. At
U.S. stocks were in the red on Friday after new cases of the coronavirus were reported in eight countries, including Mexico and Nigeria. The Dow Jones Industrial Average fell 3.37% to 24,898, the S&P 500 Index lost 2.80% to 2,895 and the Nasdaq Composite Index declined 2.15% to 8,382.
Non-index stocks have posted gains and losses recently. Shares of Autodesk Inc. (ADSK) jumped almost 2% on Friday after the company announced fourth-quarter results. The company posted
Sands Capital Management recently disclosed its portfolio updates for the fourth quarter of 2019.
Founded in 1992 by Frank M. Sands Sr., Sands Capital Management is a staff-owned independent investment management firm that invests in high-quality growth business. Frank Sands (Trades, Portfolio) Jr. joined the firm in 2000 and now serves as CEO and Chief Investment Officer. The Arlington, Virginia-based firm has two main concentrated growth strategies: Select Growth, which chooses innovative businesses, and Global Growth, which diversifies holdings in countries outside of the U.S. Sands Capital Management has achieved success by focusing on its six investment
As our understanding of how cancer works evolves, so too are the methods that we are taking to treat the condition. In my opinion, one of the most important breakthroughs in the field of oncology today is immunotherapy.
With the first form of immunotherapy approved for an oncology indication in 1997, this approach to the treatment of cancer is relatively young. However, it is also incredibly promising.
Instead of focusing on harmful treatment options that not only attack cancer, but also attack healthy tissue, leading to severe adverse events, immunotherapies enable the body’s own immune
U.S. stocks were in positive territory on Monday, heading into a week full of monetary policy meetings for severalÂ central banks.The Dow Jones Industrial Average gained 0.24% to 26,152, the S&P 500 index advanced 0.28% to 2,895 and the Nasdaq Composite Index jumped 0.83% to 7,861.
Shares of Castle Brands Inc. (ROX) gained more than 6% on Monday after the company announced fourth-quarter results. Revenue grew 11.7% from the prior-year quarter to $26.89 million, beating analysts’estimates by $1.98 million. Earnings were 5 cents per share.
"This was an outstanding year for Castle Brands," President and CEOÂ MOS
Cancer is a devastating ailment. While the oncology field has progressed in leaps and bounds over the past couple of decades, there are still many cancer types that come with few solutions and high mortality rates.
The cancer treatment market is a massive one, and the companies that produce these treatments often make strong investment opportunities. By the year 2026, it is expected that the oncology market will be worth $126.9 billion. With so much financial opportunity in the space and several areas with medical need, oncology stocks tend to be met with heavy
U.S. stocks were in positive territory on Tuesday despite uncertainty recarding company's quarterly financial results. The Dow Jones Industrial Average rose 120 points to 24,028, the S&P 500 index gained 0.95% to 2,607 and the Nasdaq Composite Index advanced 1.61% to 7,017.
Shares of Big 5 Sporting Goods Corp. (BGFV) jumped more than 12% in Tuesday after the company announced same-store sales rose 1.1% in the fourth quarter. Net sales were $247.1 million, up from $242.9 million in the prior-year quarter.
For the full year, net sales were $987.6 million, down from $1.01 billion in fiscal 2017.
U.S. stocks were in negative territory on Thursday after Apple (AAPL) lowered its outlook for the fiscal first quarter of 2019 on Wednesday. The Dow Jones Industrial Average fell more than 500 points to 22,828, the S&P 500 index declined 1.80% to 2,464 and the Nasdaq Composite Index retreated 2.29% to 6,513.
Shares of Bristol-Myers Squibb Co. (BMY) fell more than 14% on Thursday after the company announced it will acquire Celgene (CELG) in a transaction valued at $74 billion.
Upon the deal's close, Bristol-Myers shareholders will own more than two-thirds of the combined company and Celgene shareholders will own
U.S. stocks advanced Thursday morning, after President Donald Trump made progress with China in a “long and very good conversation” with the country's president, Xi Jinping. The Dow Jones Industrial Average rose more than 200 points, or 0.89% to 25,339. The S&P 500 index gained 0.76% to 2,732, and the Nasdaq Composite Index advanced 1.07% to 7,383.
Shares of Fabrinet (FN) jumped more than 2% on Thursday after the company posted third-quarter earnings of 24 cents per share, on revenue of $435.88 million, reflecting 26.7% year-over-year growth. The company beat earnings estimates by 2 cents and revenue expectations by $6.91
U.S. stocks advanced on Wednesday morning with benchmarks nearly all-time highs, as investors are awaiting the Federal Reserve decision on interest rates in the afternoon. The Dow Jones Industrial Average traded up 0.19% to 26,542, the S&P 500 index rose 0.25% to 2,922, while the Nasdaq Composite Index increased by 0.37% to 8,036.
Shares of AAR Corp. (AIR) jumped more than 6% on Wednesday morning after the company posted first quarter earnings per share of 54 cents on $466.3 million in revenue, reflecting 17.2% year-over-year growth. The company beat earnings estimates by 2 cents and revenue estimations by $13.37 million.
According to the GuruFocus All-In-One Screener, the following health care stocks are popular among guru investors.
Eight gurus are invested in Seattle Genetics Inc. (SGEN). The biotech company develops therapies for the treatment of cancer. It has a market cap of $12.41 billion. Its revenue of $575.66 million has climbed 26.40% over a 10-year period.
The stock is trading with a price-book ratio of 8.97. As of Friday, the price of $78 is 2.25% below its 52-week high and 61.34% above its 52-week low. Over the last 10 years, it has returned a gain of 551%.
The company’s largest
U.S. stock markets were trading in positive territory on Tuesday, ahead of positive economic data from a report from the New York-based Conference Board, which showed that consumer confidence rose in August to the highest level since October 2000.
Shares of DSW Inc. (DSW) jumped more than 20% on Tuesday morning after the company posted second-quarter earnings per share of 63 cents on revenue of $795.27 million, reflecting 16.4% year-over-over growth. It beat earnings estimates by 17 cents and revenue estimates by $105.9 million.
Further, comparable sales rose 9.7%, and reported gross profit, as a percent of sales, increased by
Almost four months of 2018 have come and gone, leaving the S&P 500 index about flat despite some manic swings. According to the All-in-One Screener, 271 stocks of the index have failed to eke gains year to date. The stocks registering the worst performance are: L Brands Inc. (LB), Incyte Corp. (INCY), Acuity Brands Inc. (AYI), The Kraft Heinz Co. (KHC) and Kimco Realty Corp. (KIM).
L Brands Inc. (LB)
L Brands stock declined 40.1% year to date, making it the worst performing stock of 2018. Up 0.13% Thursday, L Brands traded for $35.51 a share.
Pharmaceutical company Incyte Corp. (INCY) announced on Friday that its skin cancer drug, in combination with Merck & Co. Inc. (MRK)'s Keytruda, failed to meet its primary objective in a late-stage study, sending shares of both companies lower.
The primary objective of the study, which was evaluating the effects of Incyte’s inhibitor, Epacadostat, and Keytruda in treating metastatic melanoma, was to determine if the drug combination would improve progression-free survival in the overall patient population compared to Keytruda alone. Keytruda is already approved for treating several forms of cancer, including lung cancer and advanced melanoma.
In addition, the company
The stock market has been off to a rough start in 2018, with many speculating about a potential crash or a bear market. On closer inspection, though, it seems clear that the market is simply undergoing a typical correction in the wake of an earlier bull market. This is a natural trend and part of stabilizing the market for further investment – and makes it safe for investors to start wondering what stocks are good contenders for spring investments.
Many Americans are anticipating tax refunds in the wake of the April 15 filing deadline, with those who qualify
According to the GuruFocus All-In-One Screener, the following health care stocks are popular among gurus.
Four gurus are invested in Acadia Pharmaceuticals Inc. (ACAD).
The biopharmaceutical company has a market cap of $3.99 billion.
The stock is trading with a price-book (P/B) ratio of 10.42. The current stock price of $32.13 is 22.01% below its 52-week high and 28.21% above its 52-week low. Over the past 10 years, it has returned a gain of 201%.
It’s okay if you want your daughter to marry a Wall Street analyst. Just don’t let one pick your stocks for you.
A study I’ve been conducting since 1998 suggests as much. Each January, I look at the four stocks analysts most adore, and the four they most despise.
The adored stocks have failed to beat the market (as measured by the Standard & Poor’s 500 Index) in 13 of the 19 years I’ve been doing the study. (I took a time-out in 2008, when I had temporarily retired as a columnist.)
The most beloved stocks have averaged an 8.9%
Analysts took action on health care stocks this week.
Incyte Corp. (INCY) has been upgraded by RBC Capital from Sector Perform to a new rating of Outperform, according to a research note dispatched by the analyst on Jan. 2.
This is the first upgrade the stock got over the last four months. During the same period, shares of Incyte Corp. started to be covered by Deutsche Bank with a hold rating and by RBC Capital with a sector perform rating.
Source: Yahoo Finance
BMO Capital maintained its Outperform rating three times on Sept. 11, Oct.
Incyte Corp. (INCY) just announced a fresh deal with small-cap biotechnology company MacroGenics Inc. (MGNX), and both companies are picking up some strength on the back of the news. MacroGenics traded at a close to 20% premium to its preannouncement market capitalization Wednesday morning. Incyte was up a couple of percentage points, having spiked in the early session but subsequently settled down.
This gain might not seem as substantial of the form, but when you consider the size of Incyte compared to that of MacroGenics, it's a solid market response to the development.
In light of this response, then, here
The U.S. stock market opened lower with the three main indexes in red, but two soon turned green.Â
Shares of Dycom Industries Inc. (DY)Â were down almost 11.5% in morning trading on the back of the company reporting better-than-expected earnings for its fourth quarter. EPS of $1.47 beat expectations by three cents and revenue of $780.2 million beat estimates by $18.26 million but declined 1.1% year over year. The company now expects total contract revenues for the next quarter to be between $715 million and $745 million. On a GAAP basis, diluted EPS is expected range between